Allianz Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Allianz Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,923	Closed	-$281K	–	2772
2019 Q3	$281K	Sell	1,923 -2,770	-59%	-$482K	﹤0.01%	2541
2019 Q2	$976K	Sell	4,693 -57	-1%	-$12.2K	﹤0.01%	2143
2019 Q1	$990K	Sell	4,750 -24	-0.5%	-$5.29K	﹤0.01%	2102
2018 Q4	$836K	Sell	4,774 -188	-4%	-$37.5K	﹤0.01%	2095
2018 Q3	$1.12M	Buy	4,962 +402	+9%	+$65K	﹤0.01%	2183
2018 Q2	$691K	Sell	4,560 -27	-0.6%	-$4.91K	﹤0.01%	2318
2018 Q1	$840K	Buy	4,587 +625	+16%	+$140K	﹤0.01%	2257
2017 Q4	$844K	Sell	3,962 -53	-1%	-$11.3K	﹤0.01%	2284
2017 Q3	$861K	Sell	4,015 -9	-0.2%	-$1.76K	﹤0.01%	2297
2017 Q2	$761K	Buy	4,024 +968	+32%	+$190K	﹤0.01%	2307
2017 Q1	$756K	Buy	+3,056	New	+$750K	﹤0.01%	2315

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Allianz Asset Management's CRBP Position: Q4 2019 in Review

Allianz Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 1,923 shares — an estimated $281K sold.

Allianz Asset Management first reported a position in CRBP in Q1 2017 and held it in 11 quarters. The position peaked at $1.12M in Q3 2018. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

Allianz Asset Management reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Allianz Asset Management sold 1,923 Corbus Pharmaceuticals shares in Q4 2019, an estimated $281K.
Allianz Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Allianz Asset Management's Corbus Pharmaceuticals position peaked at $1.12M in Q3 2018.
105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Allianz Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.